Medtronic (NYSE:MDT) touted results demonstrating the superiority of two of its cryoablation therapy technologies.
Fridley, Minn.-based Medtronic said in a news release that trials showed the superiority of the Arctic Front advance cardiac cryoballoon and the Freezor max cardiac cryoablation catheter for the first-line treatment (before drug therapy) of recurrent symptomatic paroxysmal atrial fibrillation (PAF) when compared to antiarrhythmic drug (AAD) treatment.
The company presented the primary results from the randomized STOP-AF first trial at the 2020 European Society of Cardiology (ESC) Congress and noted that 12-month outcomes from the Cryo-First trial showed significant improvements in atrial fibrillation-related quality of life with the use of Medtronic’s cryoablation system compared to anti-arrhythmic drug therapy in patients who hadn’t previously received anti-arrhythmic drugs to treat their symptomatic PAF.
